Guanylate cyclase 2C GUCY2C expression and the tumor immune microenvironment TIME in gastrointestinal GI cancers


Paul Sackstein, Harris Krause, Andrew Elliott, Heinz-Josef Lenz, Francesca Battaglin, Ajay Prakash, Emil Lou, Matthew Oberley, Andreas Seeber, Richard M. Goldberg, Axel Grothey, Anthony Shields, John Marshall, Sanjay Goel, Benjamin Weinberg


  • An immunosuppressive TIME can reduce the efficacy of immune checkpoint inhibitors (ICI) in GI cancers.
  • GUCY2C is preferentially expressed in colorectal (CRC), gastroesophageal junction (EJC) and gastric adenocarcinoma (GA).
  • There is currently an ongoing trial of GUCY2C-directed bispecific T cell engager in advanced GI cancers.
  • Better characterization of the TIME of GUCY2C-high GI cancers will be important as additional directed immunotherapies are developed.
Download Publication